ChiCTR2100043581 版本V1.3 版本创建时间2021/06/14 04:40:40 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100043581 

最近更新日期:

Date of Last Refreshed on:

2021-06-14 04:38:16 

注册时间:

Date of Registration:

2021-02-23 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

银质针导热治疗对早期足底筋膜炎的治疗效果观察,一项前瞻性、双盲、多中心、随机对照试验

Public title:

Observation of the therapeutic effect of silver needle heat conduction therapy on early plantar fasciitis, a prospective, double-blind, multi-center, randomized controlled trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

银质针导热治疗对早期足底筋膜炎的治疗效果观察,一项前瞻性、双盲、多中心、随机对照试验

Scientific title:

Observation of the therapeutic effect of silver needle heat conduction therapy on early heel pain, a prospective, double-blind, multi-center, randomized controlled trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

孟超 

研究负责人:

孟超 

Applicant:

Chao Meng 

Study leader:

Chao Meng 

申请注册联系人电话:

Applicant telephone:

+86 18661808786

研究负责人电话:

Study leader's
telephone:

+86 18661808786

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

mengchao1119@hotmail.com

研究负责人电子邮件:

Study leader's E-mail:

mengchao1119@hotmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

山东省青岛市黄岛区五台山路1677号

研究负责人通讯地址:

山东省青岛市黄岛区五台山路1677号

Applicant address:

1677 Wutaishan Road, Huangdao District, Qingdao, Shandong, China

Study leader's address:

1677 Wutaishan Road, Huangdao District, Qingdao, Shandong, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

青岛大学附属医院

Applicant's institution:

the Affiliated Hospital of Qingdao University

研究负责人所在单位:

青岛大学附属医院

Affiliation of the Leader:

the Affiliated Hospital of Qingdao University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

QYFYKYLL937311920

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

青岛大学附属医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Qingdao University Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2021-02-24 00:00:00

伦理委员会联系人:

朱婕

Contact Name of the ethic committee:

Jie Zhu

伦理委员会联系地址:

山东省青岛市市南区江苏路16号

Contact Address of the ethic committee:

16 Jiangsu Road, Shinan District, Qindao, Shandong, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

青岛大学附属医院

Primary sponsor:

the Affiliated Hospital of Qingdao Univeristy

研究实施负责(组长)单位地址:

山东省青岛市黄岛区五台山路1677号

Primary sponsor's address:

1677 Wutaishan Road, Huangdao District, Qingdao, Shandong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东

市(区县):

Country:

China

Province:

Shandong

City:

单位(医院):

青岛大学附属医院

具体地址:

山东省青岛市黄岛区五台山路1677号

Institution
hospital:

the Affiliated Hospital of Qingdao Univeristy

Address:

1677 Wutaishan Road, Huangdao District, Qingdao

国家:

中国

省(直辖市):

黑龙江省

市(区县):

Country:

China

Province:

Heilongjiang

City:

单位(医院):

哈尔滨医科大学附属第二医院

具体地址:

黑龙江省哈尔滨市南岗区学府路246号

Institution
hospital:

the Second Affiliated Hospital of Harbin Medical University

Address:

246 Xuefu Road, Nangang District, Harbin

国家:

中国

省(直辖市):

山东

市(区县):

Country:

China

Province:

Shandong

City:

单位(医院):

滨州医学院附属医院

具体地址:

山东省滨州市黄河二路661号

Institution
hospital:

Binzhou Medical University Hospital

Address:

661 Second Huanghe Road, Binzhou

国家:

中国

省(直辖市):

云南省

市(区县):

Country:

China

Province:

Yunnan

City:

单位(医院):

玉溪市人民医院

具体地址:

云南省玉溪市红塔区聂耳路二十一号

Institution
hospital:

People’s Hospital of Yuxi City

Address:

21 Nieer Road, Hongta District, Yuxi

国家:

中国

省(直辖市):

黑龙江

市(区县):

Country:

China

Province:

Heilongjiang

City:

单位(医院):

哈尔滨医科大学附属第四医院

具体地址:

黑龙江省哈尔滨市南岗区颐园街37号

Institution
hospital:

the Fourth Affiliated Hospital of Harbin Medical University

Address:

37 Yiyuan Street, Nangang District, Harbin

经费或物资来源:

自筹

Source(s) of funding:

Self-financing

研究疾病:

足底筋膜炎  

Target disease:

Plantar Fasciitis

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

足底筋膜炎早期常伴有肿胀,我们探讨单纯的足底减压与减压的同时进行热疗,对足底筋膜炎治疗效果的观察。  

Objectives of Study:

Plantar fasciitis is often accompanied by swelling in the early stage. We try to observe the treatment of plantar fasciitis by performing hyperthermia with simple plantar decompression and decompression.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

足底筋膜炎的诊断由具有十多年专业经验的疼痛学专家做出。年龄18-60岁,持续时间1-3月并伴有足跟部肿胀;未进行局部激素和或局麻药注射、外科手术等有创操作;VAS评分晨起第一步脚跟疼痛≥5分或进行日常活动时脚跟疼痛≥5分;Roles and Maudsley score可/差;接受热敷、冰敷、按摩、口服NSAIDs类药物至少3天;如果合适,可以进行磁共振成像(MRI),神经传导速度/肌电图检查或其他诊断测试,以确认足底筋膜炎或排除其他诊断。

Inclusion criteria

The diagnosis of plantar fasciitis is made by a pain expert with more than ten years of professional experience. 18-60 years old, duration 1-3 months with heel swelling; no local hormone and or local anesthetic injection, surgical operation and other invasive operations; VAS score in the morning, first step heel pain ≥ 5 points or proceed Heel pain during daily activities ≥5 points; Roles and Maudsley score is acceptable/poor; receive hot compress, ice compress, massage, oral NSAIDs for at least 3 days; if appropriate, magnetic resonance imaging (MRI), nerve conduction velocity/muscle Electrographic examination or other diagnostic tests to confirm plantar fasciitis or rule out other diagnoses.

排除标准:

治疗区域的活动性感染或慢性感染病史,全身性炎性疾病,神经或血管功能不全,神经压迫症状,凝血功能紊乱,双侧足底疼痛,足手术史,怀孕,糖尿病,肿瘤、长期阿片类药物或皮质类固醇激素服用史,酗酒,无法正常交流或精神类疾病

Exclusion criteria:

History of active infection or chronic infection in the treatment area, systemic inflammatory disease, nerve or vascular insufficiency, nerve compression symptoms, coagulation disorders, bilateral plantar pain, history of foot surgery, pregnancy, diabetes, tumors, long-term opioids History of taking drugs or corticosteroids, alcohol abuse, inability to communicate normally, or mental illness

研究实施时间:

Study execute time:

From 2021-03-08 00:00:00 To 2022-07-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-03-08 00:00:00 To 2022-03-07 00:00:00

干预措施:

Interventions:

组别:

银质针导热治疗组

样本量:

400

Group:

Test

Sample size:

干预措施:

银质针导热治疗

干预措施代码:

Intervention:

silver needle heat conduction therapy

Intervention code:

组别:

对照组

样本量:

400

Group:

Control

Sample size:

干预措施:

单纯银质针

干预措施代码:

Intervention:

silver needle therapy

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山东 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

青岛大学附属医院 

单位级别:

三甲医院 

Institution
hospital:

the Affiliated Hospital of Qingdao Univeristy

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

黑龙江 

市(区县):

 

Country:

Chian

Province:

Heilongjiang

City:

单位(医院):

哈尔滨医科大学附属第二医院 

单位级别:

三甲医院 

Institution
hospital:

the Second Affiliated Hospital of Harbin Medical University

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

黑龙江 

市(区县):

 

Country:

China

Province:

Heilongjiang

City:

单位(医院):

哈尔滨医科大学附属第四医院 

单位级别:

三甲医院 

Institution
hospital:

the Fourth Affiliated Hospital of Harbin Medical University

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

山东 

市(区县):

 

Country:

China

Province:

Shandong

City:

单位(医院):

滨州医学院附属医院 

单位级别:

三甲医院 

Institution
hospital:

Binzhou Medical University Hospital

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

云南省 

市(区县):

 

Country:

China

Province:

Yunnan

City:

单位(医院):

玉溪市人民医院 

单位级别:

三甲医院 

Institution
hospital:

People’s Hospital of Yuxi City

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

VAS

指标类型:

主要指标

Outcome:

VAS

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Roles and Maudsley score

指标类型:

主要指标

Outcome:

Roles and Maudsley score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

VAS降低比例

指标类型:

次要指标

Outcome:

reduction of VAS

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

满意度

指标类型:

次要指标

Outcome:

satisfaction

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机数字表

Randomization Procedure (please state who generates the random number sequence and by what method):

Random number table

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

中国临床试验注册中心 http://www.chictr.org.cn/

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

http://www.chictr.org.cn/

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-02-23 06:22:39